Physician profile
Doris A Rodriguez
NPI 1548286446
$6,372.54
in general payments reported to CMS, 2019-2025
35 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $159 · 2021: $495 · 2022: $1,754 · 2023: $543 · 2024: $1,611 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,797.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,448.91 | 2022-2025 | |
| Allergan, INC. | $1,289.47 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $611.91 | 2022-2024 | Ingrezza, Ongentys |
| Abbvie INC. | $457.43 | 2021-2025 | Ubrelvy, Qulipta |
| Ucb, INC. | $346.40 | 2019-2025 | Rystiggo, Fintepla, Nayzilam |
| Neurelis, INC. | $215.16 | 2022-2025 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $195.34 | 2023-2025 | Hyqvia, Gammagard |
| Alexion Pharmaceuticals, INC. | $178.00 | 2019-2025 | Ultomiris |
| Greenwich Biosciences, INC. | $158.37 | 2021 | |
| Sk Life Science, INC. | $157.92 | 2021-2025 | |
| Argenx US, INC. | $148.45 | 2022-2024 | Vyvgart Hytrulo |
| Eisai INC. | $143.72 | 2023-2024 | |
| Tg Therapeutics, INC. | $111.67 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $98.19 | 2019-2025 | Austedo Xr, Austedo Xr |
| Revance Therapeutics, INC. | $85.72 | 2025 | Daxxify |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $80.55 | 2021 | |
| Pfizer INC. | $77.21 | 2023-2025 | |
| Genentech USA, INC. | $67.37 | 2021-2022 | |
| Lundbeck LLC | $52.72 | 2019-2020 | |
| Lilly USA, LLC | $47.72 | 2023-2024 | Amyvid, Emgality |
| E.R. Squibb & Sons, L.L.C. | $47.29 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $45.98 | 2021-2025 | Wainua |
| Acadia Pharmaceuticals INC | $36.67 | 2023-2025 | Nuplazid |
| Vertex Pharmaceuticals Incorporated | $36.25 | 2024 | |
| Livanova USA, INC. | $33.53 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mallinckrodt Hospital Products INC. | $29.76 | 2025 | Acthar |
| Avanir Pharmaceuticals, INC. | $29.56 | 2019 | |
| Biogen, INC. | $24.29 | 2025 | Leqembi |
| Novartis Pharmaceuticals Corporation | $23.07 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.46 | 2022 | |
| Boston Scientific Corporation | $21.41 | 2022 | |
| Amgen INC. | $15.34 | 2019 | |
| Emd Serono, INC. | $14.99 | 2020 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Aucta Pharmaceuticals, INC. | $7.55 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.